Preventing recurrence of high-risk type 1 AIP
Part of Digestive system, Immune system & allergy clinical trials.
This trial studies a treatment to prevent recurrence in people with type 1 autoimmune pancreatitis (AIP) who are at high risk. It looks at how well the treatment works and whether it can keep the disease from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with type 1 autoimmune pancreatitis (AIP) and are at high-risk for recurrence
- You have symptoms (like jaundice or pain) or are symptom-free but have signs of organ damage
- You are willing to take oral medication and follow the study procedures
- If you are a woman who could become pregnant, you must agree to use contraception starting one month before and throughout the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called inebilizumab for type 1 autoimmune pancreatitis, a condition where the immune system attacks the pancreas. The goal is to see if this treatment can reduce symptoms and prevent damage to the pancreas and other organs.
This trial is testing an oral medication called ivarmacitinib, which may help protect the insulin-making cells in your pancreas and slow down the progression of type 1 diabetes. It is designed for people who have just been diagnosed with type 1 diabetes.
This trial follows the natural course of recurrent acute pancreatitis and tests how well treatments work for it.
This trial tests if pirfenidone, an anti-scarring drug, can reduce the number of repeat episodes of acute pancreatitis. You may be eligible if you've had two or more pancreatitis attacks at least three months apart and are not having an active attack right now.
This trial tests if removing the gallbladder can prevent future episodes of unexplained acute pancreatitis. It may help people who've had one to three episodes with no clear cause found.
This trial tests a medication (a GLP-1 agonist) to see if it can prevent another pancreatitis attack caused by very high triglycerides. If you recently had such an attack, this treatment might lower your risk of it happening again.
Hear when a new Type 1 AIP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.